Small molecule tools for functional interrogation of protein tyrosine phosphatases

FEBS Journal

Volumn 280, Issue 2, 2013, Pages 731-750

  He, Rongjun ^a   Zeng, Li Fan ^a   He, Yantao ^a   Zhang, Sheng ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemical probes; fragment based focus library; high throughput screening; potency and specificity; protein tyrosine phosphatases; small molecule inhibitors; structure based design; tyrosine phosphorylation; virtual screening

Indexed keywords

2 [4 OXO 5 [3 PHENYLALLYLIDENE] 2 THIOXOTHIAZOLIDIN 3 YL]ETHANE SULFONIC ACID; 2 BENZYLIDENE 3 (CYCLOHEXYLAMINO) 2,3 DIHYDRO 1H INDEN 1 ONE; 2 OXO 1,2 DIHYDROBENZO[CD]INDOLE 6 SULFONAMIDE DERIVATIVE; AURINTRICARBOXYLIC ACID; CD45 INHIBITOR; CDC25A INHIBITOR; CDC25B INHIBITOR; CDC25C INHIBITOR; HE PROTEIN TYROSINE PHOSPHATASE INHIBITOR; I 11; I A09; II B08; LTV 1; MPTPA INHIBITOR; NSC 87877; NSC 95397; PHENYLHYDRAZONOPYRAZOLONE SULFONIC ACID; PIPERAZINYL THIOPHENYL ETHYL OXALAMIDE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEIN TYROSINE PHOSPHATASE BETA INHIBITOR; PROTEIN TYROSINE PHOSPHATASE GAMMA INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PTPRO INHIBITOR; SANGUINARINE; SPI 112; TAUTOMYCETIN; TC PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; BINDING AFFINITY; CRYSTAL STRUCTURE; DEPRESSION; DIABETES MELLITUS; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME BINDING; GRAFT REJECTION; HUMAN; IC 50; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CANCER; MYCOBACTERIUM TUBERCULOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NOONAN SYNDROME; OBESITY; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84872783533     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08718.x     Document Type: Review

References (129)

1. Hunter T, (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21, 140-146.
2. Tonks NK, &, Neel BG, (2001) Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 13, 182-195.
3. Zhang ZY, (2001) Protein tyrosine phosphatases: prospects for therapeutics. Curr Opin Chem Biol 5, 416-423.
4. Arena S, Benvenuti S, &, Bardelli A, (2005) Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci 62, 2092-2099.
5. Ostman A, Hellberg C, &, Bohmer FD, (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6, 307-320.
6. Ventura JJ, &, Nebreda AR, (2006) Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 8, 153-160.
7. Julien SG, Dubé N, Hardy S, &, Tremblay ML, (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11, 35-49.
8. Blume-Jensen P, &, Hunter T, (2001) Oncogenic kinase signaling. Nature 411, 355-365.
9. Krause DS, &, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353, 172-187.
10. Jänne PA, Gray N, &, Settleman J, (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8, 709-723.
11. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, &, Mustelin T, (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711.
12. Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S, &, Knapp S, (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352-363.
13. Zhang ZY, (2003) Mechanistic studies on protein tyrosine phosphatases. Prog Nucleic Acid Res Mol Biol 73, 171-220.
14. Tonks NK, (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7, 833-846.
15. Simoncic PD, McGlade CJ, &, Tremblay ML, (2006) PTP1B and TC-PTP: novel roles in immune-cell signaling. Can J Physiol Pharmacol 84, 667-675.
16. Elchelby M, Payette P, Michaliszyn E, Cromlish W, Collins S, Lee Loy A, Normandin D, Cheng A, Himms-Hagen J, Chan CC, et al. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 283, 1544-1548.
17. Klaman LD, Boss Q, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, et al. (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20, 5479-5489.
18. Neel BG, Gu H, &, Pao L, (2003) The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28, 284-293.
19. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt L, Crosby AH, Ion A, Jeffery S, et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29, 465-468.
20. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, &, Gelb BD, (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34, 148-150.
21. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, et al. (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64, 8816-8820.
22. Smukste I, &, Stockwell BR, (2005) Advances in chemical genetics. Annu Rev Genomics Hum Genet 6, 261-286.
23. Tjernberg A, Hallén D, Schultz J, James S, Benkestock K, Byström S, &, Weigelt J, (2004) Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B). Bioorg Med Chem Lett 14, 891-895.
24. Guertin KR, Setti L, Qi L, Dunsdon RM, Dymock BW, Jones PS, Overton H, Taylor M, Williams G, Sergi JA, et al. (2003) Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg Med Chem Lett 13, 2895-2898.
25. Wang Q, Dubé D, Friesen RW, LeRiche TG, Bateman KP, Trimble L, Sanghara J, Pollex R, Ramachandran C, Gresser MJ, et al. (2004) Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry 43, 4294-4303.
26. Bova MP, Mattson MN, Vasile S, Tam D, Holsinger L, Bremer M, Hui T, McMahon G, Rice A, &, Fukuto JM, (2004) The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide. Arch Biochem Biophys 429, 30-41.
27. Blaskovich MA, (2009) Drug discovery and protein tyrosine phosphatases. Curr Med Chem 16, 2095-2176.
28. Combs AP, (2010) Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 53, 2333-2344.
29. Barr AJ, (2010) Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem 2, 1563-1576.
30. Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, &, Wu J, (2010) Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 16, 1843-1862.
31. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, &, Zhang ZY, (1997) Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci USA 94, 13420-13425.
32. Zhang ZY, (2002) Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol 42, 209-234.
33. He Y, Zeng LF, Yu ZH, He R, Liu S, &, Zhang ZY, (2012) Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. Bioorg Med Chem 20, 1940-1946.
34. Tonks NK, (2003) PTP1B: from the sidelines to the front lines! FEBS Lett 546, 140-148.
35. Lessard L, Stuible M, &, Tremblay ML, (2010) The two faces of PTP1B in cancer. Biochim Biophys Acta 1804, 613-619.
36. Dubé N, &, Tremblay ML, (2004) Beyond the metabolic function of PTP1B. Cell Cycle 3, 550-553.
37. Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, &, Zhang ZY, (2001) Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem 276, 47311-47319.
38. Sun JP, Fedorov AA, Lee SY, Guo XL, Shen K, Lawrence DS, Almo SC, &, Zhang ZY, (2003) Crystal structure of PTP1B in complex with a potent and selective bidentate inhibitor. J Biol Chem 278, 12406-12414.
39. Xie L, Lee SY, Andersen JN, Waters S, Shen K, Guo XL, Moller NPH, Olefsky JM, Lawrence DS, &, Zhang ZY, (2003) Cellular effects of small molecule PTP1B inhibitors on insulin signalling. Biochemistry 42, 12792-12804.
40. Lee SY, Liang F, Guo XL, Xie L, Cahill SM, Blumenstein M, Yang H, Lawrence DS, &, Zhang ZY, (2005) Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angew Chem Int Ed 44, 4242-4244.
41. Boutselis IG, Yu X, Zhang ZY, &, Borch R, (2007) Synthesis and cell-based activity of a potent and selective PTP1B inhibitor prodrug. J Med Chem 50, 856-864.
42. Lau CK, Bayly CI, Gauthier JY, Li CS, Therien M, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, et al. (2004) Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 14, 1043-1048.
43. Combs AP, Zhu WY, Crawley ML, Glass B, Polam P, Sparks RB, Modi D, Takvorian A, McLaughlin E, Yue EW, et al. (2006) Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. J Med Chem 49, 3774-3789.
44. Arora SK, Banerjee R, Kamboj RK, Loriya R, Suthar B, Dixit R, Waghchoure A, Goel R, &, Sreedhara Swamy KH, (2009). Novel protein tyrosine phosphatase-1B inhibitors. PCT Int Appl, WO 2009/109998.
45. Lakshminarayana N, Prasad YR, Gharat L, Thomas A, Narayanan S, Raghuram A, Srinivasan CV, &, Gopalan B, (2010) Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem 45, 3709-3718.
46. Fukuda S, Ohta T, Sakata S, Morinaga H, Ito M, Nakagawa Y, Tanaka M, &, Matsushita M, (2010) Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes Obes Metab 12, 299-306.
47. You-ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, &, Tremblay ML, (1997) Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 186, 683-693.
48. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, &, McGlade CJ, (2002) The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol 12, 446-453.
49. Tiganis T, Bennett AM, Ravichandran KS, &, Tonks NK, (1998) Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol Cell Biol 18, 1622-1634.
50. Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, Puryer MA, Meng TC, Tonks NK, &, Tiganis T, (2003) Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Mol Cell Biol 23, 2096-2108.
51. van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, Tremblay ML, &, Tiganis T, (2005) Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat Immunol 6, 253-260.
52. Zhang S, Chen L, Luo Y, Gunawan A, Lawrence DS, &, Zhang ZY, (2009) Acquisition of a potent and selective TC-PTP inhibitor from a stepwise fluorophore-tagged combinatorial synthesis and screening strategy. J Am Chem Soc 131, 13072-13079.
53. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, &, Shoelson SE, (1998) Crystal structure of the SH2 domain phosphatase SHP-2. Cell, 98, 441-450.
54. Tiganis T, &, Bennett AM, (2007) Protein tyrosine phosphatase function: the substrate perspective. Biochem J 402, 1-15.
55. Noren-Muller A, Reis-Correa I, Prinz H, Rosenbaum C, Saxena K, Schwalbe HJ, Vestweber D, Cagna G, Schunk S, Schwarz O, et al. (2006) Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc Natl Acad Sci USA 103, 10606-10611.
56. Chen LW, Sung SS, Yip MLR, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, &, Wu J, (2006) Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 70, 562-570.
57. Lawrence HR, Pireddu R, Chen LW, Luo YT, Sung SS, Szymanski AM, Yip MLR, Guida WC, Sebti SM, Wu J, et al. (2008) Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem 51, 4948-4956.
58. Hellmuth K, Grosskopf S, Lum CT, Wurtele M, Roder N, Kries JPV, Rosario M, Rademann J, &, Birchmeier W, (2008) Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci USA 105, 7275-7280.
59. Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, et al. (2010) Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem 53, 2482-2493.
60. Yu ZH, Chen L, Wu L, Liu S, Wang L, &, Zhang ZY, (2011) Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. Bioorg Med Chem Lett 21, 4238-4242.
61. Liu S, Yu Z, Yu X, Huang SX, Luo Y, Wu L, Shen W, Yang Z, Wang L, Gunawan AM, et al. (2011) SHP2 is a target of the immunosuppressant tautomycetin. Chem Biol 18, 101-110.
62. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, et al. (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36, 337-338.
63. Bottini N, Vang T, Cucca F, &, Mustelin T, (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18, 207-213.
64. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, et al. (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75, 330-337.
65. Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alexander HC, Chang M, Catanese JJ, Leong DU, Ardlie KG, et al. (2005) PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet 77, 567-581.
66. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, et al. (2004) The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 89, 5862-5865.
67. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, et al. (2004) Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53, 3020-3023.
68. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B, Tranchant C, Gajdos P, &, Garchon HJ, (2006) Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. J Ann Neurol 59, 404-407.
69. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, et al. (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75, 504-507.
70. Yu X, Sun JP, He Y, Guo XL, Liu S, Zhou B, Hudmon A, &, Zhang ZY, (2007) Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci USA 104, 19767-19772.
71. Wu S, Bottini M, Rickert RC, Mustelin T, &, Tautz L, (2009) In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. ChemMedChem 4, 440-444.
72. Stanford SM, Krishnamurthy D, Falk MD, Messina R, Debnath B, Li S, Liu T, Kazemi R, Dahl R, He Y, et al. (2011) Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem 54, 1640-1654.
73. Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R, Yang L, Musumeci L, Francis D, &, Landskron J, (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8, 437-446.
74. Karver MR, Krishnamurthy D, Kulkarni RA, Bottini N, &, Barrios AM, (2009) Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes. J Med Chem 52, 6912-6918.
75. Zanke B, Suzuki H, Kishihara K, Mizzen L, Minden M, Pawson A, &, Mak TW, (1992) Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur J Immunol 22, 235-239.
76. Saxena M, Williams S, Brockdorff J, Gilman J, &, Mustelin T, (1999) Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J Biol Chem 274, 11693-11700.
77. Zanke B, Squire J, Griesser H, Henry M, Suzuki H, Patterson B, Minden M, &, Mak TW, (1994) A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia, 8, 236-244.
78. Bobkova EV, Liu WH, Colayco S, Rascon J, Vasile S, Gasior C, Critton DA, Chan X, Dahl R, Su Y, et al. (2011) Inhibition of the hematopoietic protein tyrosine phosphatase by phenoxyacetic acids. ACS Med Chem Lett 2, 113-118.
79. Sergienko E, Xu J, Liu WH, Dahl R, Critton DA, Su Y, Brown BT, Chan X, Yang L, Bobkova EV, et al. (2012) Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation. ACS Chem Biol 7, 367-377.
80. Pingel JT, &, Thomas ML, (1989) Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell 58, 1055-1065.
81. Prickett TC, &, Hart DN, (1990) Anti-leucocyte common (CD45) antibodies inhibit dendritic cell stimulation of CD4 and CD8 T-lymphocyte proliferation. Immunology 69, 250-256.
82. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB, Kantarci O, Schaefer-Klein J, et al. (2000) A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 26, 495-499.
83. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, &, Mullan M, (2000) CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci 20, 7587-7594.
84. Bataille R, Robillard N, Pellat-Deceunynck C, &, Amiot M, (2003) A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 194, 105-111.
85. Beers SA, Malloy EA, Wu W, Wachter MP, Gunnia U, Cavender D, Harris C, Davis J, Brosius R, Pellegrino-Gensey JL, et al. (1997) Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45. Bioorg Med Chem 5, 2203-2211.
86. Urbanek RA, Suchard SJ, Steelman GB, Knappenberger KS, Sygowski LA, Veale CA, &, Chapdelaine MJ, (2001) Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J Med Chem 44, 1777-1793.
87. Hamaguchi T, Takahashi A, Kagamizono T, Manaka A, Sato M, &, Osada H, (2000) Synthesis and characterization of a potent and selective protein tyrosine phosphatase inhibitor, 2-[(4-methylthiopyridin-2-yl)methylsufinyl] benzimidazole. Bioorg Med Chem Lett 10, 2657-2660.
88. Hamaguchi T, Takahashi A, Manaka A, Sato M, &, Osada H, (2001) TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions. Int Arch Allergy Immunol 126, 318-324.
89. Winderlich M, Keller L, Cagna G, Broermann A, Kamenyeva O, Kiefer F, Deutsch U, Nottebaum AF, &, Vestweber D, (2009) VE-PTP controls blood vessel development by balancing Tie-2 activity. J Cell Biol 185, 657-671.
90. Baumer S, Keller L, Holtmann A, Funke R, August B, Gamp A, Wolburg H, Wolburg-Buchholz K, Deutsch U, &, Vestweber D, (2006) Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 107, 4754-4762.
91. Dominguez MG, Hughes VC, Pan L, Simmons M, Daly C, Anderson K, Noguera-Troise I, Murphy AJ, Valenzuela DM, Davis S, et al. (2007) Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci USA 104, 3243-3248.
92. Lund IK, Andersen HS, Iversen LF, Olsen OH, Møller KB, Pedersen AK, Ge Y, Holsworth DD, Newman MJ, Fu A, et al. (2004) Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase ß. J Biol Chem 279, 24226-24235.
93. Amarasinghe KKD, Evidokimov AG, Xu K, Clark CM, Maier MB, Srivastava A, Colson AO, Gerwe GS, Stake GE, Howard BW, et al. (2006) Design and synthesis of potent, non-peptidic inhibitors of HPTPß. Bioorg Med Chem Lett 16, 4252-4256.
94. LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Boghosian-Sell L, Glick J, Weston A, et al. (1991) Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 88, 5036-5040.
95. Lamprianou S, Vacaresse N, Suzuki Y, Meziane H, Buxbaum JD, Schlessinger J, &, Harroch S, (2006) Receptor protein tyrosine phosphatase γ is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development. Mol Cell Biol 26, 5106-5119.
96. Sheriff S, Beno BR, Zhai W, Kostich WA, McDonnell PA, Kish K, Goldfarb V, Gao M, Kiefer SE, Yanchunas J, et al. (2011) Small molecule receptor protein tyrosine phosphatase γ (RPTPγ) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop. J Med Chem 54, 6548-6562.
97. Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C, &, Jacob ST, (2004) Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci USA 101, 13844-13849.
98. Stepanek L, Stoker AW, Stoeckli E, &, Bixby JL, (2005) Receptor tyrosine phosphatases guide vertebrate motor axons during development. J Neurosci 25, 3813-3823.
99. Pixley FJ, &, Stanley ER, (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14, 628-638.
100. Bombrun A, Hooft van Huijsduijnen R, Jorand-Lebrun C, Vitte PA, &, Gerber P, (2007) Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders. PCT WO2007009959.
101. Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, et al. (2009) GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. J Biol Chem 284, 11385-11395.
102. Todd JL, Rigas JD, Rafty LA, &, Denu JM, (2002) Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene 21, 2573-2583.
103. Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, Louis-dit-Sully C, Moutschen M, Jiang W, &, Mustelin T, (2006) Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 8, 524-531.
104. Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, et al. (2009) Multidentate small-molecule inhibitors of Vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem 52, 6716-6723.
105. Hirai G, Tsuchiya A, Koyama Y, Otani Y, Oonuma K, Dodo K, Simizu S, Osada H, &, Sodeoka M, (2011) Development of a Vaccinia H1-related (VHR) phosphatase inhibitor with a nonacidic phosphate-mimicking core structure. ChemMedChem 6, 617-622.
106. Keyse SM, (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27, 253-261.
107. Doddareddy MR, Rawling T, &, Ammit AJ, (2012) Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators. Curr Med Chem 19, 163-173.
108. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, &, Lazo JS, (2005) The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 280, 19078-19086.
109. Lazo JS, Skoko JJ, Werner S, Mitasev B, Bakan A, Koizumi F, Yellow-Duke A, Bahar I, &, Brummond KM, (2007) Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library. J Pharmacol Exp Ther 322, 940-947.
110. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, et al. (2009) Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 5, 680-687.
111. Rudolph J, (2007) Cdc25 phosphatases: structure, specificity, and mechanism. Biochemistry 46, 3595-3604.
112. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, &, Beach D, (1995) Cdc25 phosphatases as potential human oncogenes. Science 269, 1575-1577.
113. Brohm D, Metzger S, Bhargava A, Muller O, Lieb F, &, Waldmann H, (2002) Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew Chem Int Ed 41, 307-311.
114. Peng H, Xie W, Kim DI, Zalkow LH, Powis G, Otterness DM, &, Abraham RT, (2000) Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. Bioorg Med Chem 8, 299-306.
115. Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, Furey W, Gussio R, Zaharevitz DW, Joo B, et al. (2002) Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 61, 720-728.
116. Black DS, &, Bliska JB, (1997) Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J 16, 2730-2744.
117. Humphreys D, Hume PJ, &, Koronakis V, (2009) The Salmonella effector SptP dephosphorylates host AAA+ ATPase VCP to promote development of its intracellular replicative niche. Cell Host Microbe 5, 225-233.
118. Singh R, Rao V, Shakila H, Gupta R, Khera A, Dhar N, Singh A, Koul A, Singh Y, Naseema M, et al. (2003) Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol Microbiol 50, 751-762.
119. Singh R, Singh A, &, Tyagi AK, (2005) Deciphering the genes involved in pathogenesis of Mycobacterium tuberculosis. Tuberculosis (Edinb) 85, 325-335.
120. Koul A, Herget T, Klebl B, &, Ullrich A, (2004) Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol 2, 189-202.
121. Liang F, Huang Z, Lee SY, Liang J, Ivanov MI, Alonso A, Bliska JB, Lawrence DS, Mustelin T, &, Zhang ZY, (2003) Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague. J Biol Chem 278, 41734-41741.
122. Bahta M, Lountos GT, Dyas B, Kim SE, Ulrich RG, Waugh DS, &, Burke TR Jr, (2011) Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase. J Med Chem 54, 2933-2943.
123. Rawls KA, Lang P, Takeuchi J, Imamura S, Baguley TD, Grundner C, Alber T, &, Ellman JA, (2009) Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med Chem Lett 19, 6851-6854.
124. Correa IR Jr, Noren-Muller A, Ambrosi HD, Jakupovic S, Saxena K, Schwalbe H, Kaiser M, &, Waldmann H, (2007) Identification of inhibitors for mycobacterial protein tyrosine phosphatase B (MptpB) by biology-oriented synthesis (BIOS). Chem Asian J 2, 1109-1126.
125. Soellner MB, Rawls KA, Grundner C, Alber T, &, Ellman JA, (2007) Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. J Am Chem Soc 129, 9613-9615.
126. Beresford NJ, Mulhearn D, Szczepankiewicz B, Liu G, Johnson ME, Fordham-Skelton A, Abad-Zapatero C, Cavet JS, &, Tabernero L, (2009) Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages. J Antimicrob Chemother 63, 928-936.
127. Tan LP, Wu H, Yang PY, Kalesh KA, Zhang X, Hu M, Srinivasan R, &, Yao SQ, (2009) A High-throughput discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitors using click chemistry. Org Lett 11, 5102-5105.
128. Zhou B, He Y, Zhang X, Xu J, Luo Y, Wang Y, Franzblau SG, Yang Z, Chan R, Liu Y, et al. (2010) Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci USA 107, 4573-4578.
129. Chen L, Zhou B, Zhang S, Wu L, Wang Y, Franzblau SG, &, Zhang ZY, (2010) Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis. ACS Med Chem Lett 14, 355-359.